Edwards Lifesciences Corp (NYSE:EW) Expected to Announce Quarterly Sales of $769.06 Million
Equities analysts expect that Edwards Lifesciences Corp (NYSE:EW) will report sales of $769.06 million for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Edwards Lifesciences’ earnings, with the lowest sales estimate coming in at $700.20 million and the highest estimate coming in at $797.03 million. Edwards Lifesciences reported sales of $1.09 billion during the same quarter last year, which would suggest a negative year over year growth rate of 29.4%. The firm is scheduled to announce its next earnings results on Tuesday, July 28th.
On average, analysts expect that Edwards Lifesciences will report full-year sales of $4.25 billion for the current fiscal year, with estimates ranging from $4.05 billion to $4.47 billion. For the next fiscal year, analysts anticipate that the business will post sales of $5.07 billion, with estimates ranging from $4.71 billion to $5.30 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Edwards Lifesciences.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.07. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. The business had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the previous year, the business earned $0.44 earnings per share. The firm’s revenue was up 13.7% on a year-over-year basis.
EW stock traded up $0.36 during trading on Friday, hitting $68.25. 34,110 shares of the company traded hands, compared to its average volume of 3,371,622. The firm has a market capitalization of $41.60 billion, a PE ratio of 38.94, a P/E/G ratio of 2.53 and a beta of 0.84. Edwards Lifesciences has a 1 year low of $51.51 and a 1 year high of $82.55. The company has a 50-day moving average of $109.88 and a 200-day moving average of $82.02. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.47 and a current ratio of 3.36.
In related news, VP Catherine M. Szyman sold 2,249 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $68.06, for a total value of $153,066.94. Following the sale, the vice president now owns 34,564 shares in the company, valued at approximately $2,352,425.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Catherine M. Szyman sold 1,116 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $216.91, for a total value of $242,071.56. Following the completion of the sale, the vice president now owns 14,755 shares in the company, valued at approximately $3,200,507.05. The disclosure for this sale can be found here. Insiders sold a total of 194,323 shares of company stock valued at $25,124,106 in the last three months. Corporate insiders own 1.48% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of EW. Procyon Private Wealth Partners LLC boosted its stake in Edwards Lifesciences by 276.3% during the 1st quarter. Procyon Private Wealth Partners LLC now owns 143 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 105 shares during the last quarter. 1776 Wealth LLC boosted its stake in Edwards Lifesciences by 97.6% during the 1st quarter. 1776 Wealth LLC now owns 162 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 80 shares during the last quarter. Balentine LLC purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $32,000. Trust Co. of Vermont boosted its stake in Edwards Lifesciences by 65.4% during the 1st quarter. Trust Co. of Vermont now owns 253 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 100 shares during the last quarter. Finally, Pinz Capital Management LP purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $60,000. Institutional investors and hedge funds own 80.66% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Further Reading: The components of the Stochastic Momentum Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.